A correction to this article is available online at https://​doi.​org/​10.​1007/​s00508-018-1428-7.
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effects has consistently been augmented, resulting in therapy modalities that are better tailored to individual patients as well as in increased safety of the treatment. The present consensus on ruxolitinib therapy management has been elaborated by Austrian experts in myeloproliferative neoplasms in line with international treatment guidelines. Our recommendations aim to contribute to an improved management of patients with myelofibrosis treated with ruxolitinib.
European Medicines Agency. Jakavi (ruxolitinib): Summary of product characteristics, 2017. http://​ec.​europa.​eu.
Vannucchi AM, Gisslinger H, Harrison CN, et al. EXPAND: a phase 1b, open-label, dose-finding study of Ruxolitinib in patients with Myelofibrosis (MF) and low platelet counts (50 × 109/L to 99 × 109/L) at baseline. Blood. 2015;126(23):2817.
Porpaczy E. JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a preexisting B‑cell clone. Blood. 2018. in press.